Huangpu to host world's largest anti-cancer bio-drug production base

Construction of the second plant of BeiGene's Guangzhou biological drug production base was completed on Dec 16, while that of its third plant began simultaneously.

Currently, the capacity of the production base has reached 24,000 liters of biological drugs, which will rise to 64,000 liters after the third plant comes into operation. It may top the country among self-owned anti-cancer biological drug production bases of domestic pharmaceutical companies.

In addition, the production base is also pushing forward the automation and intellectualization of its plants, relying on new technologies like augmented reality glasses, digital twinning, artificial intelligence, as well as 3D modeling and modular design. It will bring in a stainless steel bioreactor to meet the increasing demands of global patients for innovative biological drugs. 

BeiGene.

Currently, cancer is a major disease that threatens the health of human beings. However, the production of high-end biological drugs is insufficient, and the prices are very high. There is an urgent need for more high-quality and affordable anti-cancer biological drugs.

BeiGene was founded by Wang Xiaodong, a member of the US National Academy of Sciences, in collaboration of John V. Oyler, who has rich management and operation experience. The enterprise has long been committed to boosting the development level of China's biopharmaceutical industry. It spent $920 million on R&D in 2019, which ranked first among domestic pharmaceutical companies.

Covering 100,000 square meters, BeiGene's Guangzhou biological drug production base began construction at China-Singapore Guangzhou Knowledge City in 2017. Work on its first plant was completed in September 2019.

Share - WeChat